Perlmutter Cancer Center at NYU Langone Hospital - Long Island — New York, New York

Perlmutter Cancer Center at NYU Langone Hospital - Long Island is a clinical research site located in New York, New York, United States 10016.

Crixeo Health Trust Score: 65/100 (FAIR). This profile has not yet been claimed by the site owner.

Perlmutter Cancer Center at NYU Langone Hospital - Long Island has participated in 3 clinical trials with 3 currently active.

Therapeutic areas: Platinum-resistant Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Bladder Cancer.

Sponsors: Genmab, Boehringer Ingelheim, UroGen Pharma Ltd..

Sponsor Feasibility Report

Trust Score: 65/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Perlmutter Cancer Center at NYU Langone Hospital - Long Island?

Perlmutter Cancer Center at NYU Langone Hospital - Long Island has a Crixeo Trust Score of 65/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Perlmutter Cancer Center at NYU Langone Hospital - Long Island conducted?

Perlmutter Cancer Center at NYU Langone Hospital - Long Island has 3 clinical trials on record, with 3 currently active. Their work covers Platinum-resistant Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Bladder Cancer.

Is Perlmutter Cancer Center at NYU Langone Hospital - Long Island accredited by Crixeo Health?

Perlmutter Cancer Center at NYU Langone Hospital - Long Island has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Perlmutter Cancer Center at NYU Langone Hospital - Long Island?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.